From RNS19 Oct 2020 11:18
Following the Company's successful partnership efforts to date, the Board of Advanced Oncotherapy expect that further commercial collaborations and purchase orders will be signed in 2021 given the Company's strong pipeline of global opportunities.
· Recent expansion of the Company's partnership with the Cleveland Clinic, which will now be able to refer cancer patients from its London facility to Advanced Oncotherapy's London Clinic site in Harley Street, is expected to result in more patients being treated at the London Clinic site, from which the Company would receive a share of the profits.
Nicolas Serandour, CEO of Advanced Oncotherapy, said:
"At today's presentation, we will reaffirm our view from the interim results that, although there have been headwinds caused as a result of Covid-19 pandemic during 2020, the Company has made strong progress and now has all the key high-precision components of the accelerator in place at Daresbury. 2021 is set to be an exciting year for the Company as we expect to have a fully operational LIGHT system with a 230MeV beam, which is the beam energy needed to treat patients. We also expect to sign further commercial agreements for new machines as we progress our robust pipeline of opportunities."
- ENDS -
Advanced Oncotherapy plc
www.avoplc.com
Dr. Michael Sinclair, Executive Chairman
Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance)
Amrit Nahal / Matt Butlin (Sales & Broking)
Tel: +44 (0) 20 3328 5656
SI Capital Ltd (Joint Broker)
Nick Emerson
Tel: +44 (0) 1483 413 500
Jon Levinson
Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR)
advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder
Tel: +44 (0) 20 3727 1000
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime p